The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study

doi:10.1038/s41398-021-01585-3

CORC > 心理研究所 > 中国科学院心理研究所 > 中国科学院心理健康重点实验室

	The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study
	Liu, Jiahong 1; Wang, Pingping 5; Sun, Leilei 4; Guan, Xiaoni 3; Xiu, Meihong 3; Zhang, Xiangyang 2
刊名	TRANSLATIONAL PSYCHIATRY
	2021-09-04
卷号	11 期号:1 页码:5
ISSN号	2158-3188
DOI	10.1038/s41398-021-01585-3
通讯作者	Xiu, Meihong(xiumeihong9797@gmail.com) ; Zhang, Xiangyang(zhangxy@psych.ac.cn)
英文摘要	A growing number of studies have shown that brain-derived neurotrophic factor (BDNF) is associated with weight gain during antipsychotic treatment in schizophrenia patients. However, there is still a lack of research results in the initial stage of antipsychotic treatment. This study aimed to evaluate the relationship between weight gain caused by risperidone monotherapy for 12 weeks and BDNF level in antipsychotic-naive and first-episode (ANFE) patients with schizophrenia, and we hypothesize that this may depend on BDNF Val66Met gene polymorphism. In a 12-week longitudinal trial, 225 ANFE patients were enrolled and treated with risperidone. Body weight was measured at baseline and during the 12-week follow-up. After treatment, the average weight of ANFE patients increased by 2.6 kg. Furthermore, we found that in patients with Val/Val genotype, the increase in serum BDNF levels was negatively correlated with risperidone-induced weight gain (r = -0.44, p = 0.008). Regression analysis showed that the baseline BDNF level was a predictor of weight gain after treatment (beta = -0.45, t = -3.0, p = 0.005). Our results suggest that the BDNF signaling may be involved in weight gain caused by risperidone treatment. Furthermore, the negative association between weight gain and increased BDNF levels during risperidone treatment in ANFE schizophrenia depends on the BDNF Val66Met polymorphism.
收录类别	SCI
WOS关键词	NEUROTROPHIC FACTOR BDNF ; BODY-MASS INDEX ; GENE POLYMORPHISMS ; DEFICIENT ; VARIANTS ; CHILDREN ; RECEPTOR ; OBESITY ; DRUGS
WOS研究方向	Psychiatry
语种	英语
出版者	SPRINGERNATURE
WOS记录号	WOS:000693037500003
内容类型	期刊论文
源URL	[http://ir.psych.ac.cn/handle/311026/40211]
专题	心理研究所_中国科学院心理健康重点实验室
通讯作者	Xiu, Meihong; Zhang, Xiangyang
作者单位	1.Wenzhou Med Univ, Affiliated Kangning Hosp, Wenzhou, Peoples R China 2.Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China 3.Peking Univ, Beijing HuiLongGuan Hosp, HuiLongGuan Clin Med Sch, Beijing, Peoples R China 4.Qingdao Univ, Qingdao Mental Hlth Ctr, Qingdao, Peoples R China 5.Capital Med Univ, Dept Neurol, Xuan Wu Hosp, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Liu, Jiahong,Wang, Pingping,Sun, Leilei,et al. The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study[J]. TRANSLATIONAL PSYCHIATRY,2021,11(1):5.
APA	Liu, Jiahong,Wang, Pingping,Sun, Leilei,Guan, Xiaoni,Xiu, Meihong,&Zhang, Xiangyang.(2021).The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study.TRANSLATIONAL PSYCHIATRY,11(1),5.
MLA	Liu, Jiahong,et al."The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study".TRANSLATIONAL PSYCHIATRY 11.1(2021):5.